journal
MENU ▼
Read by QxMD icon Read
search

Clinical Pharmacology in Drug Development

journal
https://www.readbyqxmd.com/read/28724202/population-pharmacokinetics-of-lenalidomide-in-healthy-volunteers-and-patients-with-hematologic-malignancies
#1
Jamie N Connarn, Renfang Hwang, Yue Gao, Maria Palmisano, Nianhang Chen
A population pharmacokinetic (PopPK) model of lenalidomide was developed using data pooled from 13 clinical studies (dose range, 5-400 mg) in participants who were considered to have adequate capability for renal excretion of lenalidomide (creatinine clearance [CrCl] > 50 mL/min). The analysis population included 305 healthy volunteers and 83 patients with multiple myeloma or myelodysplastic syndromes. A 1-compartment model with linear absorption and elimination described well the observed data for both healthy volunteers and patients...
July 19, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28628269/effect-of-food-intake-on-the-pharmacokinetics-of-a-novel-methylphenidate-extended-release-oral-suspension-for-attention-deficit-hyperactivity-disorder
#2
Floyd R Sallee, Donna R Palumbo, Richat Abbas, Sally A Berry, Shivanand P Puthli, Kalyan K Kathala
We conducted an open-label, single-dose, randomized, crossover study in healthy adults to assess the impact of food on the bioavailability of 60 mg methylphenidate extended-release oral suspension (MEROS; Quillivant XR™)-a long-acting stimulant for the treatment of attention deficit hyperactivity disorder-by comparing the pharmacokinetic parameters under fed and fasting conditions. When MEROS 60 mg was administered under fed conditions compared with fasting conditions, the exposure of methylphenidate (d enantiomer) was higher, with a mean area under the plasma concentration-vs-time curve (AUC)0-t of 160...
June 19, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28597973/safety-tolerability-and-pharmacokinetics-of-single-and-multiple-oral-doses-of-an-omega-3-carboxylic-acid-formulation-in-healthy-male-japanese-subjects-a-phase-1-single-blind-randomized-placebo-controlled-trial
#3
Yoshinori Noda, Catarina Nilsson, Hitoshi Shimada, Hyosung Kim, Torbjörn Lundström, Toshitaka Yajima
OM3-CA (omega-3-carboxylic acids) is a complex mixture of omega-3 carboxylic acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which is approved in the United States for the treatment of hypertriglyceridemia. As part of its clinical development in Japan, we performed a phase 1 study to investigate the safety, tolerability, and pharmacokinetics after single and multiple doses of OM3-CA in healthy male Japanese subjects. Eighteen Japanese subjects were allocated to receive 2 or 4 g/day OM3-CA, or placebo (n = 6 per group)...
June 9, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28581645/effects-of-a-nutritional-protein-rich-drink-on-the-pharmacokinetics-of-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-and-tenofovir-compared-with-a-standard-meal-in-healthy-japanese-male-subjects
#4
REVIEW
Hiroyuki Yamada, Ippei Ikushima, Takanori Nemoto, Tomohiro Ishikawa, Noriko Ninomiya, Shin Irie
This study investigated the effects of ingested meal types on the pharmacokinetics of elvitegravir (EVG), cobicistat (COBI), emtricitabine (FTC), tenofovir alafenamide (TAF), and tenofovir (TFV) following a single administration of the single-tablet regimen (STR) of EVG/COBI/FTC/TAF (150/150/200/10 mg) in Japanese HIV-negative healthy subjects (n = 12). In this open-label, randomized, 3-way crossover study, the bioequivalence of the EVG/COBI/FTC/TAF STR following ingestion of a nutritional protein-rich drink with a reference treatment of taking a standard breakfast was evaluated...
June 5, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28556598/single-and-multiple-day-dosing-studies-to-investigate-high-dose-pharmacokinetics-of-epelsiban-and-its-metabolite-gsk2395448-in-healthy-female-volunteers
#5
Kelly M Mahar, Mary Beth Enslin, Angie Gress, Heather Amrine-Madsen, Melisa Cooper
Open-label single- and double-blind repeat-dose studies in healthy female volunteers were conducted to investigate the pharmacokinetics (PK) and safety/tolerability of epelsiban total daily doses ranging from 600 to 900 mg. In 1 study (n = 12), epelsiban was dosed at 300 or 450 mg twice daily (every 12 hours) for a single day. In the repeat-dose double-blind study, epelsiban and placebo were administered to 31 subjects as 200 mg 3 times daily, 300 mg 3 times daily (TID), or 450 mg twice daily (BID) for 14 days...
May 26, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28544581/a-comparison-of-the-pharmacokinetics-of-methylphenidate-extended-release-orally-disintegrating-tablets-with-a-reference-extended-release-formulation-of-methylphenidate-in-healthy-adults
#6
Ann Childress, Jeffrey G Stark, Russ McMahen, Dorothy Engelking, Carolyn Sikes
Extended-release (ER) methylphenidate (MPH) is a first-line treatment for attention-deficit/hyperactivity disorder. A methylphenidate extended-release orally disintegrating tablet (MPH XR-ODT) has recently been developed. This was a randomized, open-label, 3-period, 3-treatment study comparing the bioavailability and absorption of 2 MPH XR-ODT formulations with an MPH ER reference medication. Here we report the 2 treatments comparing the commercial MPH XR-ODT formulation and reference medication. Following a ≥10-hour fast, 42 healthy adults received 60 mg of reference medication or MPH XR-ODT (2 × 30 mg)...
May 25, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28544344/fed-and-fasted-administration-of-a-novel-extended-release-methylphenidate-orally-disintegrating-tablet-formulation-for-the-treatment-of-adhd
#7
Richard H Weisler, Jeffrey G Stark, Carolyn Sikes
Extended-release methylphenidate is a first-line treatment for attention-deficit/hyperactivity disorder. A methylphenidate extended-release orally disintegrating tablet (MPH XR-ODT) has recently been developed. Here we report an open-label, randomized, 2-period, 2-treatment crossover study to determine the effect of food on the bioavailability of a single 60-mg dose of MPH XR-ODT in healthy adults. Blood samples were collected predose through 36 hours postdose. Maximum plasma concentration (Cmax ), time to maximum plasma concentration (Tmax ), terminal elimination half-life (T1/2 ), overall systemic exposure (AUClast and AUCinf ), and partial areas under the concentration curve (AUC0-3 , AUC3-7 , and AUC7-12 ) were calculated...
May 25, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28464496/pharmacokinetics-safety-and-tolerability-following-single-and-multiple-doses-of-pibrentasvir-in-a-first-in-human-study
#8
Chih-Wei Lin, Sandeep Dutta, Armen Asatryan, Haoyu Wang, Jack Clifton, Andrew Campbell, Wei Liu
This first-in-human dose-ascending study investigated pharmacokinetics, safety, and tolerability of pibrentasvir following single and multiple doses in healthy volunteers. Additionally, the effects of food and ritonavir on pibrentasvir were assessed in a crossover study design. The starting dose of pibrentasvir was selected based on the no-observed-adverse-effect-level exposure from preclinical studies. Dose escalations of subsequent cohorts were dependent on reviews of the safety, tolerability, and pharmacokinetic data from previous dose cohorts...
May 2, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28444716/the-relative-bioavailability-of-ibuprofen-after-administration-with-a-novel-soft-chewable-drug-formulation
#9
Magnus N Hattrem, Morten J Dille, Tore Seternes, Thorfinn Ege, Kurt I Draget
The first aim of the present study was to evaluate the bioavailability of ibuprofen dispersed in a novel soft chewable formulation compared with a traditional ibuprofen tablet; its second was to map the quality of taste masking and patient product satisfaction. In a phase 1, single-center, open-label, randomized, crossover study, healthy subjects received a soft-chew formulation or a hard tablet (reference), both containing 100 mg ibuprofen. Serial blood samples were collected over 24 hours to assess ibuprofen bioavailability...
April 25, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28475821/some-thoughts-about-the-mean-concentration-versus-time-plot
#10
Michael J Fossler
No abstract text is available yet for this article.
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28475820/the-journal-of-clinical-pharmacology-clinical-pharmacology-in-drug-development-and-the-impact-factor
#11
EDITORIAL
Joseph S Bertino, David J Greenblatt
No abstract text is available yet for this article.
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28371303/a-comparative-pharmacokinetic-study-of-2-pemetrexed-formulations-in-indian-adult-chemonaive-patients-with-adenocarcinoma-stage-iii-iv-non-small-cell-lung-cancer
#12
Krunal Kavathiya, Murari Gurjar, Anand Patil, Madhura Naik, Vanita Noronha, Amit Joshi, Vikram Gota, Kumar Prabhash
The study aimed to compare the pharmacokinetics of 2 pemetrexed formulations (Pemgem, Dr. Reddy's Laboratories w.r.t; Alimta, Eli Lilly) in adult chemonaive subjects with adenocarcinoma stage III/IV non-small cell lung cancer. All patients received 500 mg/m(2) pemetrexed (Alimta or Pemgem) as a 10-minute infusion on day 1 of a 21-day cycle. Plasma pemetrexed concentrations were determined on day 1 of cycle 1. Area under the concentration-time curve (AUC0-inf ) and the maximum plasma concentration (Cmax ) were estimated using noncompartment analysis and compared between the 2 arms...
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27545871/effect-of-the-wetting-agent-sodium-lauryl-sulfate-on-the-pharmacokinetics-of-alectinib-results-from-a-bioequivalence-study-in-healthy-subjects
#13
Peter N Morcos, Neil Parrott, Ludger Banken, Carsten Timpe, Marc Lindenberg, Elena Guerini, Georgina Dall, Katrijn Bogman, Carolina Sturm, Ali Zeaiter, Meret Martin-Facklam, Alex Phipps
The anaplastic lymphoma kinase (ALK) inhibitor alectinib is an effective treatment for ALK-positive non-small-cell lung cancer. This bioequivalence study evaluated the in vivo performance of test 3 formulations with the reduced wetting agent sodium lauryl sulfate (SLS) content. This randomized, 4-period, 4-sequence, crossover study compared alectinib (600 mg) as 25%, 12.5%, and 3% SLS hard capsule formulations with the reference 50% SLS clinical formulation in healthy subjects under fasted conditions (n = 49), and following a high-fat meal (n = 48)...
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27545757/clinical-drug-drug-interactions-through-cytochrome-p450-3a-cyp3a-for-the-selective-alk-inhibitor-alectinib
#14
Peter N Morcos, Yumi Cleary, Elena Guerini, Georgina Dall, Katrijn Bogman, Luigi De Petris, Santiago Viteri, Walter Bordogna, Li Yu, Meret Martin-Facklam, Alex Phipps
The efficacy and safety of alectinib, a central nervous system-active and selective anaplastic lymphoma kinase (ALK) inhibitor, has been demonstrated in patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) progressing on crizotinib. Alectinib is mainly metabolized by cytochrome P450 3A (CYP3A) to a major similarly active metabolite, M4. Alectinib and M4 show evidence of weak time-dependent inhibition and small induction of CYP3A in vitro. We present results from 3 fixed-sequence studies evaluating drug-drug interactions for alectinib through CYP3A...
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27545511/analgesic-efficacy-of-a-new-immediate-release-extended-release-formulation-of-ibuprofen-results-from-single-and-multiple-dose-postsurgical-dental-pain-studies
#15
Steven Christensen, Ed Paluch, Shyamalie Jayawardena, Stephen Daniels, Suzanne Meeves
Analgesic effects of ibuprofen immediate-release/extended-release (IR/ER) 600-mg tablets were evaluated in 2 randomized, double-blind, placebo-controlled dental pain studies. Patients 16-40 years old with moderate-severe pain following third-molar extraction received single-dose ibuprofen 600 mg IR/ER (formulation A or B), naproxen sodium 220 mg, or placebo (2:2:2:1; study 1) or 4 doses of ibuprofen 600 mg IR/ER (formulation A) or placebo (1:1; study 2). In study 1 (n = 196), mean (standard deviation [SD]) time-weighted sum of pain intensity difference scores for placebo, ibuprofen IR/ER A, ibuprofen IR/ER B, and naproxen, respectively, were 0...
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27545119/a-randomized-phase-1-study-to-assess-the-safety-and-pharmacokinetics-of-the-subcutaneously-injected-anti-light-antibody-sar252067
#16
Meng Zhang, Laurent Perrin, Patricia Pardo
LIGHT, a member of the tumor necrosis factor superfamily, is potentially involved in mucosal inflammation associated with inflammatory bowel disease. The safety and pharmacokinetics of the fully human monoclonal anti-LIGHT antibody, SAR252067, was evaluated in healthy volunteers in a phase 1 study as a potential treatment for diseases related to LIGHT-mediated mucosal inflammation. This double-blind, randomized, placebo-controlled, sequential ascending single-dose, single-center, 16-week study randomized 48 subjects to a single subcutaneous dose of SAR252067 (40, 120, 300, 600, 900, or 1200 mg) or placebo...
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27364955/dose-dependent-effect-of-piragliatin-a-glucokinase-activator-on-the-qt-interval-following-short-term-multiple-doses-in-patients-with-type-2-diabetes-mellitus
#17
Jianguo Zhi, Suoping Zhai, Mark Boldrin
To determine the effect of piragliatin on the QTcS (QT-corrected study-specific) interval, a double-blind, double-dummy, placebo-controlled, active-comparator, 4-period, 4-treatment, 4-sequence randomized crossover trial was performed in 42 patients with type 2 diabetes mellitus who received 100 and 200 mg piragliatin twice daily, placebo, and 400 mg moxifloxacin (on day 1 and day 5 only) for 5 days. In the categorical analyses, piragliatin did not have a clinically significant effect on the QTcS interval at either dose, and the majority of patients were categorized with low risk for maximum change from baseline (≤30 milliseconds) and a maximum postbaseline QTcS interval as normal (≤450 milliseconds)...
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27364771/plasma-pharmacokinetics-of-veledimex-a-small-molecule-activator-ligand-for-a-proprietary-gene-therapy-promoter-system-in-healthy-subjects
#18
Hongliang Cai, Lei Sun, John Miao, Suma Krishman, Francois Lebel, John A Barrett
Major obstacles to developing effective immunotherapy are the ability of tumors to escape the immune system and the toxicity associated with systemic administration. To overcome these challenges, a gene delivery platform technology, RheoSwitch Therapeutic System (RTS), has been developed to enable the regulated expression of a target gene, Ad-RTS-IL-12, administered intratumorally, where IL-12 expression is controlled via the administration of an oral activator ligand, veledimex. Pharmacokinetics in healthy human subjects indicated that veledimex plasma exposure increased with increasing dose after single- and multiple-dose administration in Labrasol slurry and F-22 capsule formulations...
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27274011/methotrexate-polyglutamate-monitoring-in-patients-with-crohn-s-disease
#19
Monika Fischer, Shivi Siva, Gwendolyn K Cook, David R Jones, Hala M Fadda
Methotrexate is an efficacious immunosuppressant for induction and maintenance of remission in Crohn's disease. The goal of this pilot study was to determine whether total or individual methotrexate glutamate levels (MTXGlun ) in red blood cells correlate with disease activity and adverse events in Crohn's disease. A cross-sectional study was undertaken with 12 patients on a stable dose of 25 mg weekly methotrexate (oral or subcutaneous). Clinical disease activity was assessed by the Harvey-Bradshaw Index (HBI), and biologic disease activity was measured by inflammatory markers...
May 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27274002/relative-bioavailability-and-bioequivalence-of-brivaracetam-10%C3%A2-mg-ml-oral-solution-and-50-mg-film-coated-tablet
#20
Christian Otoul, Shikiko Watanabe, Suzanne McCabe, Armel Stockis
No abstract text is available yet for this article.
May 2017: Clinical Pharmacology in Drug Development
journal
journal
43835
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"